Engineers Gate Manager LP Akebia Therapeutics, Inc. Transaction History

Engineers Gate Manager LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$0.72 - $2.93 $57,651 - $234,610	-80,072 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$2.26 - $3.34 $180,962 - $267,440	80,072 New	80,072 $181,000
Q1 2021 May 17, 2021	SELL	$2.92 - $5.06 $129,356 - $224,157	-44,300 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$2.22 - $3.78 $327,894 - $558,306	-147,700 Reduced 76.93%	44,300 $124,000
Q3 2020 Nov 16, 2020	BUY	$2.39 - $13.08 $458,880 - $2.51 Million	192,000 New	192,000 $482,000

120

54.8M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $324M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

Stay updated on Engineers Gate Manager LP with notifications on news.